The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 0.33 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M 1.58 — flag raised, worth a closer lookWatch
- Earnings quality 46/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as RIGEL PHARMACEUTICALS INC reports it. History and quarterly detail are in the app.
- Total product sales, net$232.0M
- Total revenues from collaborations$62.0M
- Release Of Share Cost Liability$40.0M
- Government contracts$265K
Leadership changes
From RIGEL PHARMACEUTICALS INC's own filings, the day they're filed.
- Michael P. Miller · directors · appointment
- Mark J. Frohlich · directors · appointment
Latest filings
- 8-K · Company announcement2026-08-04
- 10-Q · Quarterly report2026-08-04
- 8-K · Company announcement2026-07-01
- 8-K · Company announcement2026-06-17
- 8-K · Company announcement2026-05-20
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about RIGEL PHARMACEUTICALS INC, every answer cited to the official filings🔒
- The Intelligence Brief — added when RIGEL PHARMACEUTICALS INC's brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.